Strategic partnership agreement signed with biotechnology company Formosa Biomedical Technology Corp.
to promote Regenerative medicine CDMO business in Taiwan.
August 1, 2025
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President and Representative Director: Hidetoshi Segi, hereinafter "Rohto Pharmaceutical") has entered into a strategic partnership agreement with Formosa Biomedical Technology Corp. (Location: Taipei City, Taiwan, CEO: Liu Hui-chi, hereinafter "Formosa Biomedical"), a leading company in the biotechnology field, on July 22, 2025, with the aim of mutually cooperating and supporting each other in expanding Regenerative medicine related businesses, and has agreed to begin discussions on the details of collaboration between the two companies.
Areas for Collaboration
- Joint development of Regenerative medicine products in Japan and Taiwan
- Collaboration in CDMO (Contract Development and Management Organization) projects in Japan and Taiwan
- Joint development of research and development seeds from both companies related to Regenerative medicine, etc.
Background and purpose of the agreement
Under our overall management vision, "Connect for Well-being," we are promoting development in the field of Regenerative medicine as part of Medical business, in addition to our OTC and Skincare Business that support people's health and happiness. In Regenerative medicine, we have been working to provide new treatment options to patients who are suffering because there are no appropriate treatments available, with the statement "Making Regenerative medicine more accessible and easier to use" as our business statement. With the signing of this agreement, the possibilities for pipeline development and CDMO business will expand not only in Japan but also in Taiwan.
About Formosa Biomedical Co., Ltd.
This company is a leading biotechnology company belonging to the Taiwan Plastics Group, one of Taiwan's world's largest corporations. It creates new possibilities in biomedical technology through a platform that integrates research, clinical trials, and manufacturing. The Taiwan Plastics Group also owns Chang Gung Medical System, Taiwan's largest hospital group, enabling collaboration with medical institutions in research and development and clinical fields.
| Representative (General Manager) |
Liu Huiyeon |
| Business details |
Research and development of Regenerative medicine formulations, GMP manufacturing, pharmaceutical sales, medical devices, clinical trials,
Research and development, manufacturing, and sales of health foods and beauty products, etc. |
| location |
9th floor, No. 380, Sec. 6, Nanjing East Road, Taipei, Taiwan |